Format

Send to

Choose Destination
J Hematol Oncol. 2016 Jun 30;9(1):52. doi: 10.1186/s13045-016-0282-1.

Novel agents in the treatment of multiple myeloma: a review about the future.

Author information

1
Department of Medicine, New York University, New York, USA.
2
Department of Medicine, New York University, New York, USA. Maher.Abdulhay@nyumc.org.
3
Perlmutter Cancer Center, New York University, New York, USA. Maher.Abdulhay@nyumc.org.
4
NYU School of Medicine, 240 East 38th Street, 19 Floor, New York, NY, 10016, USA. Maher.Abdulhay@nyumc.org.

Abstract

Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An enhanced understanding of MM disease mechanisms has led to new more targeted treatments. There is now a plethora of treatments available for MM. In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM. These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.

KEYWORDS:

AKT inhibitors; Alkylating agents; BTK inhibitors; CDK inhibitors; HDACIs; IL-6 inhibitors; Immunomodulators; Kinesin spindle protein inhibitors; Monoclonal antibodies; Multiple myeloma; Novel agents; PI3K inhibitors; Proteasome inhibitors

PMID:
27363832
PMCID:
PMC4929712
DOI:
10.1186/s13045-016-0282-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center